Key Takeaways
- • LYFE Capital, a global healthcare-focused private equity and venture capital firm, is set to acquire Medians Co., a South Korean cosmeceutical manufacturer, for up to $147 million.
- • The deal was reported by investment banking sources in Seoul, according to KED Global, and has not been confirmed by the parties in the available source material.
- • The transaction is framed as part of the continued growth of Korea's K-beauty sector, which has drawn increasing private capital interest.
Summary
LYFE Capital, a global healthcare-focused private equity and venture capital firm, is set to acquire Medians Co., a South Korean cosmeceutical manufacturer, for up to $147 million, according to investment banking sources in Seoul who spoke on Sunday, as reported by KED Global.
The figure is an upper bound, indicating the consideration may vary depending on final terms. The available reporting does not specify the stake being acquired, the deal structure, or whether the transaction has been formally signed or closed.
The deal is positioned against the backdrop of the K-beauty boom, in which Korean cosmetics and skincare brands have attracted strong international demand. For private equity and venture investors, cosmeceutical manufacturers, which combine cosmetic and pharmaceutical-style product development, represent a segment of interest within Korea's broader beauty and healthcare markets.
The figure is an upper bound, indicating the consideration may vary depending on final terms. The available reporting does not specify the stake being acquired, the deal structure, or whether the transaction has been formally signed or closed.
The deal is positioned against the backdrop of the K-beauty boom, in which Korean cosmetics and skincare brands have attracted strong international demand. For private equity and venture investors, cosmeceutical manufacturers, which combine cosmetic and pharmaceutical-style product development, represent a segment of interest within Korea's broader beauty and healthcare markets.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.